Ástralía - enska - Department of Health (Therapeutic Goods Administration)

actegy pty ltd - 35372 - analgesic tens system - revitive device delivers electrical muscle stimulation (ems) to your feet and may: ? reduce pain and discomfort in the in the leg, foot and ankle caused by poor ? circulation (peripheral arterial disease) ? improve circulation in the legs caused by peripheral arterial disease ? improve circulation to reduce or prevent blood-pooling (stasis) - caused by poor ? circulation (chronic venous insufficiency/varicose veins ? increase walking distance before the onset of claudication symptoms (pain) ? ? caused by peripheral arterial disease ? improve symptoms associated with varicose veins/ chronic venous insufficiency ? reduce swelling in the knee caused by osteoarthritis ? reduce swelling volume and discomfort in the lower leg, foot and ankle due to ? prolonged inactivity and/or a sedentary lifestyle, in healthy individuals. ? reduce swelling in the ankle following acute ankle injury ? improve circulation in the legs caused by being immobile following lower limb ? surgery ? support and improve blood circulation, due to prolonged inactivity and/or a ? sedentary lifestyle, in healthy individuals ? reduce pain and discomfort in the legs caused by diabetic peripheral neuropathy ? reduce pain and discomfort associated with knee osteoarthritis ? reduce pain and discomfort in the legs following knee surgery ? increase muscle strength in the legs of people with knee osteoarthritis ? increase muscle strength in the legs of people affected by copd ? increase muscle strength in the legs of patients following lower limb surgery

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

actegy pty ltd - 35372 - analgesic tens system - revitive device delivers electrical muscle stimulation (ems) to your feet and may: ? reduce pain and discomfort in the in the leg, foot and ankle caused by poor ? circulation (peripheral arterial disease) ? improve circulation in the legs caused by peripheral arterial disease ? improve circulation to reduce or prevent blood-pooling (stasis) - caused by poor ? circulation (chronic venous insufficiency/varicose veins ? increase walking distance before the onset of claudication symptoms (pain) ? ? caused by peripheral arterial disease ? improve symptoms associated with varicose veins/ chronic venous insufficiency ? reduce swelling in the knee caused by osteoarthritis ? reduce swelling volume and discomfort in the lower leg, foot and ankle due to ? prolonged inactivity and/or a sedentary lifestyle, in healthy individuals. ? reduce swelling in the ankle following acute ankle injury ? improve circulation in the legs caused by being immobile following lower limb ? surgery ? support and improve blood circulation, due to prolonged inactivity and/or a ? sedentary lifestyle, in healthy individuals ? reduce pain and discomfort in the legs caused by diabetic peripheral neuropathy ? reduce pain and discomfort associated with knee osteoarthritis ? reduce pain and discomfort in the legs following knee surgery ? increase muscle strength in the legs of people with knee osteoarthritis ? increase muscle strength in the legs of people affected by copd ? increase muscle strength in the legs of patients following lower limb surgery when using revitive to deliver transcutaneous electrical nerve stimulation (tens), it is intended to provide: ? temporary relief of lower back pain ? relief of chronic elbow or shoulder pain caused by injury or overuse ? relief of chronic pain in the knee caused by osteoarthritis ? relief of chronic neuropathic pain ? temporary relief of post-surgical pain in the knee

Írland - enska - HPRA (Health Products Regulatory Authority)

a.vogel ireland limited - extract (as dry extract) from fresh horse chesnut seeds (aesculus hippocastanum l. semen) - gastro-resistant tablet - .

Ísrael - enska - Ministry of Health

truemed ltd. - estradiol as hemihydrate; norethisterone acetate - patches - estradiol as hemihydrate 3.2 mg; norethisterone acetate 11.2 mg - estradiol, combinations - estradiol, combinations - hormone replacement therapy for the relief of menopausal symptoms.

Ísrael - enska - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ethinylestradiol; gestodene - film coated tablets - ethinylestradiol 0.015 mg; gestodene 0.06 mg - gestodene and estrogen - gestodene and estrogen - contraceptive.

Ísrael - enska - Ministry of Health

bayer israel ltd - norethisterone acetate - tablets - norethisterone acetate 5 mg - norethisterone - norethisterone - oral progestron for: dysfunctional bleeding, primary and secondary amenorrhea, premenstrual syndrome, timing of mensturation and endometriosis.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 2.32 mg (equivalent: estradiol, qty 2.25 mg) - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; isopropyl palmitate; ethyl acetate; acrylic acid; 2-ethylhexyl acrylate; methyl acrylate; glycidyl methacrylate; 2,2'-azobisisobutyronitrile; hexane - menopausal symptoms: short-term treatment of signs and symptoms of oestrogen deficiency due to menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (refer to section 5.1 pharmacodynamic properties - clinical trials and section 4.2 dose and method of administration). prevention of post-menopausal bone mineral density loss: estraderm mx 50, 75 and 100 may be used for prevention of post-menopausal bone mineral density loss in women with an increased risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. when prescribed solely for the prevention of postmenopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for, non-oestrogen products approved for prevention of bone mineral density loss. lifestyle modifications and the risk-benefit profile of estraderm mx should be taken into careful consideration and discussed with the patient to allow the patient to make an informed decision prior to prescribing (see section 4.4 special warnings and precautions for use and section 4.2 dose and method of administration). combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase risk of breast cancer.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 3.09 mg (equivalent: estradiol, qty 3 mg) - drug delivery system, transdermal - excipient ingredients: isopropyl palmitate; polyethylene terephthalate; ethyl acetate; acrylic acid; 2-ethylhexyl acrylate; methyl acrylate; glycidyl methacrylate; 2,2'-azobisisobutyronitrile; hexane - menopausal symptoms: short-term treatment of signs and symptoms of oestrogen deficiency due to menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (refer to section 5.1 pharmacodynamic properties - clinical trials and section 4.2 dose and method of administration). prevention of post-menopausal bone mineral density loss: estraderm mx 50, 75 and 100 may be used for prevention of post-menopausal bone mineral density loss in women with an increased risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. when prescribed solely for the prevention of postmenopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for, non-oestrogen products approved for prevention of bone mineral density loss. lifestyle modifications and the risk-benefit profile of estraderm mx should be taken into careful consideration and discussed with the patient to allow the patient to make an informed decision prior to prescribing( see section 4.4 special warnings and precautions for use and section 4.2 dose and method of administration). combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase risk of breast cancer.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 0.77 mg (equivalent: estradiol, qty 0.75 mg) - drug delivery system, transdermal - excipient ingredients: isopropyl palmitate; polyethylene terephthalate; ethyl acetate; acrylic acid; 2-ethylhexyl acrylate; methyl acrylate; glycidyl methacrylate; 2,2'-azobisisobutyronitrile; hexane - menopausal symptoms: short-term treatment of signs and symptoms of oestrogen deficiency due to menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (refer to section 5.1 pharmacodynamic properties - clinical trials and section 4.2 dose and method of administration). estraderm mx 25 is not indicated for the prevention of post-menopausal bone mineral density loss. combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase risk of breast cancer

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 1.54 mg (equivalent: estradiol, qty 1.5 mg) - drug delivery system, transdermal - excipient ingredients: isopropyl palmitate; polyethylene terephthalate; ethyl acetate; acrylic acid; 2-ethylhexyl acrylate; methyl acrylate; glycidyl methacrylate; 2,2'-azobisisobutyronitrile; hexane - menopausal symptoms: short-term treatment of signs and symptoms of oestrogen deficiency due to menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (refer to section 5.1 pharmacodynamic properties - clinical trials and section 4.2 dose and method of administration). prevention of post-menopausal bone mineral density loss: estraderm mx 50, 75 and 100 may be used for prevention of post-menopausal bone mineral density loss in women with an increased risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. when prescribed solely for the prevention of postmenopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for, non-oestrogen products approved for prevention of bone mineral density loss. lifestyle modifications and the risk-benefit profile of estraderm mx should be taken into careful consideration and discussed with the patient to allow the patient to make an informed decision prior to prescribing (see section 4.4 special warnings and precautions for use and sectoin 4.2 dose and method of administration). combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase risk of breast cancer.